Press Release
Dr. Shervin Naderi Named a 2025 Castle Connolly Top Doctor
This announcement underscores Dr. Shervin Naderi's dedication to delivering exceptional care and achieving outstanding results for his patients. As a 2025 Castle Connolly Top Doctor, Dr. Naderi continues to set the standard for excellence in facial plastic surgery, inspiring confidence and trust among patients nationwide. Read More
Press Release
CBD Life Sciences Inc. (CBDL) Announces Its Official Launch on Groupon.com
Groupon, with over 22.5 million active users and generating more than $550 million in annual revenue, now features CBDL's top-tier wellness products, unlocking massive e-commerce potential and positioning the company for explosive growth in the booming CBD industry. Read More
Press Release
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth. Read More
Press Release
Envision Pharma Group Launches EnvisionOne Vantage
EnvisionOne Vantage enables medical affairs professionals to benchmark their publication performance against other companies, providing crucial competitive intelligence and valuable insights for strategic adjustments to publication strategies. Read More
Press Release
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Trial taking place at Sheikh Khalifa Medical City, a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID Proof-of-concept (POC) data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for these rare/orphan diseases Read More
Press Release
